- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Cellyan Biotechnology Co., Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 17.07. | Cellyan Biotechnology Stock Sinks 21% After Hours: Here's What Happened | 1 | Benzinga.com | ||
| 16.07. | Cellyan Biotechnology erhält 180-tägige Fristverlängerung für Nasdaq-Compliance | 1 | Investing.com Deutsch | ||
| 16.07. | Cellyan Biotechnology gets 180-day extension for Nasdaq compliance | 1 | Investing.com | ||
| 16.07. | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period | 166 | GlobeNewswire (Europe) | HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen | |
| 16.07. | Cellyan Biotechnology Co., Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| CELLYAN BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 27.03. | Cellyan Biotechnology Co., Ltd - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 18.03. | Cellyan Biotechnology Co., Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.01. | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency | 291 | GlobeNewswire (Europe) | HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen | |
| 17.12.25 | Hong Kong Pharma Digital Technology Holdings Limited Announced Results of 2025 Annual Meeting of Stockholders | 1.697 | GlobeNewswire (Europe) | HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 47,790 | -0,56 % | Bayer bekommt im Glyphosat-Poker mehr Zeit - High Noon am 14. Sepember | Die Entscheidung beim Glyphosat-Vergleich verzögert sich. Doch die Verschiebung könnte Bayer sogar helfen. Am 14. September steht bei dem 7,25-Milliarden-US-Dollar-Deal viel auf dem Spiel für die Leverkusener.... ► Artikel lesen | |
| GSK | 21,230 | -2,12 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK auf "Buy" mit einem Kursziel von 2500 Pence belassen. Das jüngst bekannt gegebene Effizienzprogramm bis 2030 bedeute... ► Artikel lesen | |
| CANOPY GROWTH | 0,862 | +0,98 % | Canopy Growth Corporation: Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows | Renewed certification maintains Kincardine's role in Canopy Growth's EU GMP flower supply chain
Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX: WEED) (Nasdaq: CGC)... ► Artikel lesen | |
| EYEPOINT | 11,700 | -8,59 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| FILANA THERAPEUTICS | 0,795 | +0,63 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,500 | -1,71 % | Warum Lillys 3,8-Milliarden-Dollar-Deal den Psychedelika-Sektor verändert - und warum Emyria jetzt in den Fokus rücken könnte | ||
| SELLAS LIFE SCIENCES | 11,100 | +0,45 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| CORBUS PHARMACEUTICALS | 8,630 | 0,00 % | Mizuho lowers Corbus Pharmaceuticals stock price target on model updates | ||
| DARE BIOSCIENCE | 0,900 | -3,23 % | Daré Bioscience, Inc.: Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances | Company launches Flora Sync LF5, the company's first directly commercialized product, began generating revenue in July DARE to PLAY Sildenafil Cream progressing toward national dispensing and initial... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,753 | -0,29 % | Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®
$17 million in cash and cash equivalents as of June 30, 2026
Expanded... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 3,240 | +5,88 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented... ► Artikel lesen | |
| EXICURE | 0,885 | +0,57 % | EXICURE, INC. - 10-Q, Quarterly Report | ||
| COSMOS HEALTH | 0,186 | -0,59 % | Cosmos Health Inc.: Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels | Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channelsCustomers can begin through one of three paths: a free... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | 3,380 | -7,62 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.08.2026 | The following instruments on XETRA do have their first trading 10.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.08.2026
Aktien
1 KYG472811036 IMC Rare Earths Ltd.
2... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 4,560 | +4,11 % | Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 Million | Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology... ► Artikel lesen |
Das Unternehmen CELLYAN BIOTECHNOLOGY CO LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,420 Euro und damit +0,02 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLYAN BIOTECHNOLOGY CO LTD finden Sie auf Wallstreet Online.